30 March - 31 March 2022

38th SCI Process Development Symposium

Organised by:

SCI's Fine Chemicals Group

Online Webinar

Register your interest
Synopsis

Process Development is the application of chemistry to the scale up of new synthetic processes from the laboratory, through pilot plant to full scale commercial manufacture and into life cycle management. It is an extremely broad discipline, crossing the boundaries between synthetic organic chemistry, process technology and chemical engineering. The area of Process Development continues to be a challenging and important area for the research into and application of modern synthetic organic chemistry, as well as enabling technologies.  


Attendees

The symposium aims to bring together a wide range of speakers from across the Pharmaceutical, Agrochemical and Fine Chemical industries, as well as from an academic background. This meeting brings together experts from across the entire spectrum of the discipline to present state of the art process development. 

 

Exhibition and Sponsorship

For further information and prices please email jacqui.maguire@soci.org

 


Programme

Confirmed speakers

The Identification of Naloxone Related Drug Product Degradants

Dr John Carey, Indivior, UK

 

Process Chemistry & Catalysis at Roche - Capabilities and selected Case Studies

Dr Stefan Hildbrand, F. Hoffmann-La Roche Ltd.

 

A long journey into MCL-1 inhibitors

Dr Matthieu Jouffroy, Janssen Pharmaceutica N.V., Belgium

 

Accelerating chemical process development through data science
Dr Jason M Stevens, Bristol Myers Squibb, USA

 

Angle control and synergistic promotion strategies in asymmetric catalysis

Prof Wanbin Zhang, Jiao Tong University, China

 

Ulrich Scholz, Boehringer Ingelheim

Dr Tom Corrie, Syngenta, UK 

 

 


Booking Process/Deadlines

Booking terms and conditions


CPD Information

SCI Members attending this meeting are able to claim CPD points.

 


Organising Committee
  • Max Espensen, Pharmaron

  • Louis Diorazio, SCI/AstraZeneca

  • Dave Lathbury, SCI/Astute Chemical Development Ltd

  • David Pascoe, SCI/GlaxoSmithKline

  • Hazmi Tajuddin, SCI/Syngenta

  • Robert Walton, SCI/Pfizer

  • Hilmar Weinman, Janssen Pharmaceutical Companies of Johnson & Johnson